Hand eczema: possible risks and choice of therapy
https://doi.org/10.21518/2079-701X-2022-16-3-32-36
Abstract
Hand eczema is a common disease – up to 5% in the general population. In addition, eczema is closely related to atopy and, like atopic dermatitis, to a mutation in the FLG gene. In addition to genetic factors, eczema is caused by external irritants and toxic substances. Eczema often occurs in families with atopic diseases, including asthma, allergic rhinitis/hay fever (and food allergies), and atopic dermatitis. These diseases share a common pathogenesis and often occur together in the same person and/or family. Eczematous rashes are often accompanied by itching. This symptom can lead not only to sleep disturbances but also to secondary infections. According to some data, the rate of infections in eczema can be more than 70%. In such cases, the drugs of choice are combined glucocorticosteroids (GC), which in addition to GC contain an antimycotic and an antibiotic. Our practical experience shows the high effectiveness of the combination of beclomethasone dipropionate, gentamicin, and clotrimazole not only in cases of eczema complicated by secondary infection but also in patients with other infected chronic dermatoses. This article reviews these and other practical aspects and problems in the treatment of hand eczema, discusses the etiological factors that lead to the development of the disease, and presents current data from clinical recommendations and guidelines for the treatment of eczema.
Supporting agencies: the article was prepared with support from Glenmark.
About the Authors
L. R. Sakaniya
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences; Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology
Russian Federation
Russian Federation
Dermatovenerologist, Junior Researcher; Dermatovenerologist, Cosmetologist, Trichologist
30, Srednyaya Kalitnikovskaya St., Moscow, 109029;
20, Seleznevskaya St., Moscow, 127473
O. Yu. Smolkina
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences; Scientific and Clinical Consulting Center of Allergology and Immunology
Russian Federation
Russian Federation
Junior Researcher; Dermatovenerologist
30, Srednyaya Kalitnikovskaya St., Moscow, 109029;
6, Ostrovityanov St., Moscow, 117513
I. M. Korsunskaya
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences; Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Laboratory
30, Srednyaya Kalitnikovskaya St., Moscow, 109029;
20, Seleznevskaya St., Moscow, 127473
References
1. Stone K.D. Atopic diseases of childhood. Curr Opin Pediatr. 2002;14(5): 634–646. https://doi.org/10.1097/00008480-200210000-00012.
2. Thomsen S.F. Epidemiology and natural history of atopic diseases. Eur Clin Res J. 2015;2(1):24642. https://doi.org/10.3402/ecrj.v2.24642.
3. Luoma R., Koivikko A., Viander M. Development of asthma, allergic rhinitis and atopic dermatitis by the age of five years. A prospective study of 543 newborns. Allergy. 1983;38(5):339–346. https://doi.org/10.1111/j.1398-9995.1983.tb04128.x.
4. Coenraads P.J., Diepgen T.L. Risk for hand eczema in employees with past or present atopic dermatitis. Inter Arch Occup Envir Health. 1998;71(1):7–13. https://doi.org/10.1007/s004200050243.
5. Meding B., Swanbeck G. Predictive factors for hand eczema. Contact Dermatitis. 1990;23(3):154–161. https://doi.org/10.1111/j.1600-0536.1990.tb04776.x.
6. Svensson Å. Hand eczema: an evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis. Acta Derm Venereol. 1988;68(6):509–513. Available at: https://pubmed.ncbi.nlm.nih.gov/2467490.
7. Williams H.C. Is the prevalence of atopic dermatitis increasing? Clin Exper Derm. 1992;17(6):385–391. https://doi.org/10.1111/j.1365-2230.1992.tb00244.x.
8. Wollenberg A., Seba A., Antal A.S. Immunological and molecular targets of atopic dermatitis treatment. Br J Derm. 2014;170(1 Suppl.):7–11. https://doi.org/10.1111/bjd.12975.
9. Benetti C., Piacentini G.L., Capristo C., Boner A.L., Peroni D.G. Microorganism‐induced exacerbations in atopic dermatitis: a possible preventive role for vitamin D? Allergy Asthma Proc. 2015;36(1):19–25. https://doi.org/10.2500/aap.2015.36.3807.
10. Irvine A.D., McLean W.H. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Inv Derm. 2006;126(6):1200–1202. https://doi.org/10.1038/sj.jid.5700365.
11. Heede N.G., Thyssen J.P., Thuesen B.H., Linneberg A., Johansen J.D. Predictive factors of self-reported hand eczema in adult Danes: a population-based cohort study with 5-year follow-up. Br J Derm. 2016;175(2):287–295. https://doi.org/10.1111/bjd.14476.
12. Kaae J., Menné T., Carlsen B.C., Zachariae C., Thyssen J.P. The hands in health and disease of individuals with filaggrin loss-of-function mutations: clinical reflections on the hand eczema phenotype. Contact Dermatitis. 2012;67(3):119–124. https://doi.org/10.1111/j.1600-0536.2012.02130.x.
13. Molin S., Merl J., Dietrich K.A., Regauer M., Flaig M., Letulé V. et al. The hand eczema proteome: imbalance of epidermal barrier proteins. Br J Derm. 2015;172(4):994–1001. https://doi.org/10.1111/bjd.13418.
14. Meding B., Järvholm B. Incidence of hand eczema - a population-based retrospective study. J Inves Derm. 2004;122(4):873–877. https://doi.org/10.1111/j.0022-202X.2004.22406.x.
15. Thyssen J.P., Johansen J.D., Linneberg A., Menné T. The epidemiology of hand eczema in the general population – prevalence and main findings. Contact Dermatitis. 2010;62(2):75–87. https://doi.org/10.1111/j.1600-0536.2009.01669.x.
16. Yngveson M., Svensson Å., Johannisson A., Isacsson Å. Hand dermatosis in upper secondary school pupils: 2-year comparison and follow-up. Br J Derm. 2000;142(3):485–489. https://doi.org/10.1046/j.1365-2133.2000.03361.x.
17. Mollerup A., Veien N.K., Johansen J.D. An analysis of gender differences in patients with hand eczema — everyday exposures, severity, and conse-quences. Contact Dermatitis. 2014;71(1):21–30. https://doi.org/10.1111/cod.12206.
18. Diepgen T.L. Occupational skin-disease data in Europe. Int Arch Occup Envir Health. 2003;76(5):331–338. https://doi.org/10.1007/s00420-002-0418-1.
19. Jensen C.S., Menné T., Johansen J.D. Systemic contact dermatitis after oral exposure to nickel: a review with a modified meta-analysis. Contact Dermatitis. 2006;54(2):79–86. https://doi.org/10.1111/j.0105-1873.2006.00773.x.
20. Ong P.Y., Leung D.Y. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev in Allergy & Immunol. 2016;51(3):329–337. https://doi.org/10.1007/s12016-016-8548-5.
21. Wang X., Shi X.D., Li L.F., Zhou P., Shen Y.W. Classification and possible bacterial infection in outpatients with eczema and dermatitis in China: A cross-sectional and multicenter study. Medicine (Baltimore). 2017;96(35):e7955. https://doi.org/10.1097/MD.0000000000007955.
22. Samtsov A.V., Khairutdinov V.R., Belousova I.E. Etiopathogenetic therapy of inflammatory dermatoses. Vestnik Dermatologii i Venerologii. 2018;94(2):78–83. (In Russ.) https://doi.org/10.25208/0042-4609-2018-94-2-78-83.
23. Sokolova T.V., Gladko V.V., Flaks G.A., Malyarchuk A.P., Safonova L.A. Microbial eczema as an infectious-dependent dermatosis in the practice of a dermatovenereologist. Moscow: Vash format; 2017. 58 p. (In Russ.) Available at: https://search.rsl.ru/ru/record/01009625137.
24. Roberts J.K., Moore C.D., Ward R.M., Yost G.S., Reilly C.A. Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013;345(2):308–316. https://doi.org/10.1124/jpet.112.202556.
25. Shahtmejster I.Ya., Shimanovskij N.L. New possibilities in the treatment of inflammatory and allergic dermatoses using an external preparation of the glucocorticoid nature methylprednisolone aceponate – advantan. Vestnik Dermatologii i Venerologii. 1999;(2):51–53. (In Russ.)
26. Svirshhevskaja E.V., Matushevkaja E.V. Comparative analysis of the clinical response and safety of fluorinated and chlorinated topical glucocorticoids. Modern Problems of Dermatology, Immunology and Medical Cosmetology. 2010;3(3):76–80. (In Russ.) Available at: https://medi.ru/info/9476.
27. Devaraj N.K., Aneesa A.R., Abdul Hadi A.M., Shaira N. Topical corticosteroids in clinical practice. Med J Malaysia. 2019;74(2):187–189. Available at: https://pubmed.ncbi.nlm.nih.gov/31079135.
28. Matushevskaya E.V., Masyukova S.A. Topical combined corticosteroids in the treatment of atopic dermatitis. Modern Problems of Dermatology, Immunology and Medical Cosmetology. 2009;2(2):14–19. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=15268091.
Review
For citations:
Sakaniya LR, Smolkina OY, Korsunskaya IM. Hand eczema: possible risks and choice of therapy. Meditsinskiy sovet = Medical Council. 2022;(3):32-36. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-3-32-36
Views:
509
Email this article 